Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SRP-1005 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort 1: SRP-1005 Dose 1 | EXPERIMENTAL | Participants will receive SRP-1005 or placebo. |
| Cohort 2: SRP-1005 Dose 2 | EXPERIMENTAL | Participants will receive SRP-1005 or placebo. |
| Cohort 3: SRP-1005 Dose 3 | EXPERIMENTAL | Participants will receive SRP-1005 or placebo. |
| Cohort 4: SRP-1005 Dose 4 | EXPERIMENTAL | Participants will receive SRP-1005 or placebo. |
| Name | Type | Description |
|---|---|---|
| SRP-1005 | DRUG | Subcutaneous injection |
| Placebo | DRUG | Subcutaneous injection |
Key Inclusion Criteria: * Genetically confirmed diagnosis of huntingtin (HTT) cytosine-adenine-guanine repeat length ≥40. * Participant has HD Integrated Staging System (HD-ISS) Stage 2 or Mild Stage 3. At screening, the participant must be classified with the Enroll-HD HD-ISS Modified Calculator a...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 2 | PHASE3 | Votoplam |
| Neurocrine Biosciences, Inc. | NBIX | 1 | PHASE3 | Valbenazine |
| Alnylam Pharmaceuticals, Inc | ALNY | 1 | PHASE1 | ALN-HTT02 |
| uniQure N.V. | QURE | 2 | PHASE1 | intra-striatal rAAV5-miHTT |
| Sarepta Therapeutics, Inc. | SRPT | 1 | PHASE1 | SRP-1005 |
SRP-1005 is an investigational small molecule being developed for the treatment of Huntington's Disease. It is currently in Phase 1 clinical development. The drug is being studied in a first-in-human trial to evaluate its effects in participants with Huntington's Disease.
The specific molecular target of SRP-1005 has not been disclosed. It is a small molecule being developed for Huntington's Disease, but its mechanism of action has not been publicly detailed.
SRP-1005 is being developed by Sarepta Therapeutics, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol SRPT. The company is conducting a Phase 1 clinical trial of SRP-1005 in participants with Huntington's Disease.
SRP-1005 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A first-in-human study is currently recruiting participants with Huntington's Disease to evaluate the drug's effects.
SRP-1005 is being studied in a Phase 1 clinical trial registered as NCT07536061, titled 'A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's Disease.' The trial is recruiting 32 participants in New Zealand and is currently active.
No alternative names for SRP-1005 have been disclosed. It is identified solely by its development code SRP-1005 and is being studied under this name in clinical trials for Huntington's Disease.